The Federal Trade Commission settled charges Friday with dietary supplement marketer Lunada Biomedical Inc. for $250,000. The company marketed its diet supplement Amberen as causing weight loss, loss of belly fat and an increase in metabolism in women over 40 who are experiencing or transitioning to menopause.
“The Lunada defendants made strong claims about the effectiveness of their supplement without the scientific evidence to back them up,” said Jessica Rich, FTC director of the consumer protection bureau, in a press release. “The relief provided by this court order is intended to prevent the defendants from making unsupported health benefit claims in the future.”
